Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Acceleron Pharma (XLRN)

Acceleron Pharma (XLRN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,174,770
  • Shares Outstanding, K 53,082
  • Annual Sales, $ 13,990 K
  • Annual Income, $ -118,870 K
  • 60-Month Beta 1.23
  • Price/Sales 163.12
  • Price/Cash Flow N/A
  • Price/Book 4.60

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.30
  • Number of Estimates 6
  • High Estimate -0.01
  • Low Estimate -0.91
  • Prior Year -0.75
  • Growth Rate Est. (year over year) +60.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
40.15 +2.04%
on 11/07/19
47.79 -14.28%
on 11/05/19
-0.95 (-2.27%)
since 10/15/19
3-Month
37.60 +8.96%
on 10/02/19
47.79 -14.28%
on 11/05/19
-4.05 (-9.00%)
since 08/15/19
52-Week
37.01 +10.70%
on 06/11/19
56.91 -28.01%
on 12/03/18
-9.69 (-19.13%)
since 11/15/18

Most Recent Stories

More News
Biotech Stock Roundup: SLDB Plunges, CELG Gets FDA Nod for Reblozyl & Other Updates

Key highlights of the past week include regulatory and pipeline updates along with collaboration deals.

GILD : 65.07 (+1.97%)
BIIB : 282.27 (+2.59%)
XLRN : 40.97 (-4.71%)
CELG : 110.02 (unch)
AMRN : 24.02 (+11.77%)
SLDB : 3.51 (+11.08%)
Celgene & Acceleron Get FDA Nod for Rare Blood Disorder Drug

Celgene (CELG) and partner Acceleron obtain FDA approval for Reblozyl for the treatment of anemia in adult patients with beta thalassemia.

BMY : 58.59 (+0.14%)
VRTX : 209.80 (+2.34%)
XLRN : 40.97 (-4.71%)
CELG : 110.02 (unch)
FDA Approves REBLOZYL(R) (luspatercept-aamt) for the Treatment of Anemia in Adults With Beta Thalassemia Who Require Regular Red Blood Cell Transfusions

--Approval of REBLOZYL marks the first FDA-approved treatment for anemia in beta thalassemia

CELGZ : 0.44 (-8.37%)
CELG : 110.02 (unch)
XLRN : 40.97 (-4.71%)
Acceleron Pharma (XLRN) Reports Q3 Loss, Tops Revenue Estimates

Acceleron (XLRN) delivered earnings and revenue surprises of -6.17% and 22.11%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

XLRN : 40.97 (-4.71%)
Acceleron Announces Luspatercept Presentations at the 61st American Society of Hematology Annual Meeting

--- In the BELIEVE Phase 3 trial, beta-thalassemia patients who were luspatercept responders had durable clinical benefit over the 64.1-week follow-up period -

XLRN : 40.97 (-4.71%)
Acceleron: 3Q Earnings Snapshot

CAMBRIDGE, Mass. (AP) _ Acceleron Pharma Inc. (XLRN) on Wednesday reported a loss of $45.4 million in its third quarter.

XLRN : 40.97 (-4.71%)
Acceleron Reports Third Quarter 2019 Operating and Financial Results

--- Six clinical abstracts accepted for presentation at the 61st American Society of Hematology (ASH) Annual Meeting -

XLRN : 40.97 (-4.71%)
11.5% Return Seen to Date on SmarTrend Acceleron Pharma Call (XLRN)

SmarTrend identified an Uptrend for Acceleron Pharma (NASDAQ:XLRN) on October 21st, 2019 at $42.65. In approximately 2 weeks, Acceleron Pharma has returned 11.49% as of today's recent price of $47.55....

XLRN : 40.97 (-4.71%)
Acceleron to Webcast Third Quarter 2019 Operating and Financial Results on November 6, 2019

Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Wednesday, November 6, 2019 at 10:00 a.m. EST to discuss its third quarter 2019 operating and financial...

XLRN : 40.97 (-4.71%)
Geron Starts Enrollment in Phase III MDS Study on Imetelstat

Geron enrolls first patient in the late-stage IMerge study to evaluate imetelstat in myelodysplastic syndromes.

JNJ : 134.94 (+3.04%)
XLRN : 40.97 (-4.71%)
CELG : 110.02 (unch)
GERN : 1.31 (-4.38%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More Share

Trade XLRN with:

Business Summary

Acceleron Pharma Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of protein therapeutics for cancer and rare diseases. Acceleron Pharma Inc. is based in Cambridge, Massachusetts.

See More

Key Turning Points

2nd Resistance Point 44.24
1st Resistance Point 42.61
Last Price 40.97
1st Support Level 40.06
2nd Support Level 39.14

See More

52-Week High 56.91
Fibonacci 61.8% 49.31
Fibonacci 50% 46.96
Fibonacci 38.2% 44.61
Last Price 40.97
52-Week Low 37.01

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar